Umlaut.bio is a preclinical biotech-company targeting the modification of tRNAs for the therapy of cancer and autoimmune diseases.
Umlaut.bio GmbH develops first-in-biology small molecules focusing on the “umlauts” of the genetic code – chemically modified RNA nucleotides. These play a crucial role in gene regulation and are of great importance, for example, in cancer cells. There, modified tRNAs protect protein-coding mRNAs from degradation and thus promote tumor growth. Therapeutic modalities that specifically address this previously undrugged fundamental biochemical principle could be able to selectively prevent the growth of cancer as well as proinflammatory cells. This approach promises a disruptive novel form of therapy.
.